Novartis gets FDA nod for groundbreaking flu vaccine; Kiadis raises $12.8M; MabVax garners $5M in venture cash;

 @FierceBiotech: Predicting your end: Biomarkers for mortality. News | Follow @FierceBiotech

 @JohnCFierce: Feds zero in on drug experts as insider case exposes investigator's role (more to come, I suspect). Story | Follow @JohnCFierce

 @RyanMFierce: With ex-BMSer Jeremy Levin at the helm, Teva wants to do buyouts that are smaller than the deals that made Teva big. More | Follow @RyanMFierce

> The FDA has approved Flucelvax from Novartis ($NVS), the first seasonal flu product made from animal cell technology. Story

> The blood-cancer drug developer Kiadis Pharma has raised $12.8 million in a round led by Life Sciences Partners with support from DFJ-Esprit, Alta Partners, Quest for Growth and NOM. Report

> MabVax Therapeutics has raised $5.25 million, with much of the money earmarked for a mid-stage study of an experimental cancer vaccine to prevent the recurrence of sarcoma. Story

> Algeta and Ablynx have struck a research collaboration to evaluate a novel Targeted Thorium Conjugate combining Algeta's proprietary thorium-227 alpha-pharmaceutical payload with "Nanobodies" generated using Ablynx's technology platform. Release

Pharma News

@FiercePharma: Novartis nabs FDA approval for 1st flu vaccine made without eggs. Produced at plant that got $500M in gov't aid. More (sub. req.) | Follow @FiercePharma

> New Teva CEO, new small-is-beautiful M&A strategy. Report

> Novartis fast production, cell-culture flu vaccine OK'd by FDA. Article

> Armed with EU stroke approval, Pfizer, BMS talk up Eliquis' edge over rivals. Story

> PwC sees golden era for pharmas that dump the junk, innovate. News

 @FierceMedDev: FDA faults St. Jude's manufacturing for Durata ICD leads. St. Jude disclosed the report but kept "Durata" out. More | Follow @FierceMedDev

 @MarkHFierce: Zimmer will train regulators in China in an unusual deal. Release | Follow @MarkHFierce

 @DamianFierce: Novartis' Alcon is buying the ophthalmic surgery unit of German company SensoMotoric. Story | Follow @DamianFierce

> Boston Scientific gets CE mark for expanded CRM longevity. Article

> HeartWare snags FDA approval for novel heart pump. News

Drug Deliver News

> Fujifilm joins microneedle R&D boom. Report

> Reinforced gels deliver drugs and cells. Article

> Pfizer hits ups, downs with controlled-release Lyrica. News

> Nanoparticles deliver antigen to trick the immune system in MS. Story

Biomarkers News

> Predicting your end: Biomarkers for mortality. Article

> Kidney problems tag development delays? Story

> Saliva markers diagnose gum disease. News

> DoD's $1.15M grant may lead to blood test to catch heavy drinkers. Item

Vaccine News

> J&J hits development roadblock with Crucell candidates. Article

> FDA panel concerned about safety of Dynavax's hep B vaccine. News

> Novartis nabs EU committee backing for meningitis B vaccine. Story

> GSK's Synflorix gleans positive results in infants. Report

> FDA approves Novartis flu vaccine. Item

And Finally… A*STAR scientists say they have identified the enzyme telomerase as a cause of chronic inflammation in human cancers. Release

 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.